Entering text into the input field will update the search result below

AMRN- The Current Scripts Have Been Updated.

Jul. 09, 2013 4:06 AM ETAMRN5 Comments
tobingj profile picture
tobingj's Blog
9 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

I am just out of the Amarin AGM- 2013. This is probably the hottest day this year. Shelbourne- 9th July.

10 staff members and one independent in the room. All motions passed. David stack voted onto Board.

A small presentation shown for the independent observer. Not much new, Jelis , Comparison of Vascepa vs lovaza, progress to date.

The current scripts have been updated. Slides to appear soon on website. There will be two new slides. YOY comparison of goals, e.g. patents July 2012, 1, patents July 2013 ,25.
Other slide is the scripts updated.

They are happy with progress- not worried with recent events such as Advisory committee appointed , Omthera etc.

I didn't ask why share price so low- as I got free coffee and biscuits. !! :)

------------------------

Edit- Presentation here.

Looking back over notes they mentioned they are 6 months ahead of where they were when Reliant launched Lovaza. I am assuming that is due to greater interest in healthcare and an increase in poor diet and general lack of exercise since 2007.

Reliant bought out for 1.65 bn

As Lovaza has run out of Patent they only had Patent for 6 to 7 years? Amarin has patent to 2030 or more. 17 years.

Disclosure: I am long AMRN.

Additional disclosure: My disclosure is based on my opinion only and relevant information taken from conference call and various other sources of information. It has no importance in you making a decision to invest your money in AMRN or not.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You